Aethlon Medical, Inc. (OTCQB: AEMD) disclosed today that the Company will provide Hemopurifier therapy under FDA compassionate use access provisions to support potential requests by qualified physicians and institutes that may seek to treat ebola virus in the United States. Aethlon also disclosed that it plans to submit its first ebola treatment data to the FDA as a means to support the goal of further expanding treatment access through emergency use regulatory pathways. CEO James Joyce stated, The administration of Hemopurifier® therapy in Germany has reinforced the need to clarify defined regulatory pathways that might allow us to treat ebola infection in the United States. As it relates to the patient treated in Germany, we respect patient confidentiality and will report on his response to therapy after Frankfurt University Hospital officials provide an update on his condition. The Company is also preparing to initiate United States clinical studies of Hemopurifier therapy based on the FDAs approval of an IDE previously submitted by the Company. Read the full press release available here: bit.ly/1wFCIQH
Posted on: Wed, 29 Oct 2014 14:10:22 +0000
Trending Topics
© 2015